Picture of Takeda Pharmaceutical Co logo

TAK Takeda Pharmaceutical Co News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareConservativeLarge CapNeutral

REG-Nippon Life Insurance Company Form 8.3 - Takeda Pharmaceutical Company Limited.

.

Form 8.3 - Takeda Pharmaceutical Company Limited.

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:   Nippon Life Insurance Company
(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

 
(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Takeda Pharmaceutical Company Limited.
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:  
(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

8/1/2019
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state “N/A”

NO

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:   Ordinary Shares of Takeda Pharmaceutical Company Limited

 

Interests   Short positions
  Number   % Number   %
(1) Relevant securities owned and/or controlled: 45,383,085 5.71    
(2) Cash-settled derivatives:        
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:        

TOTAL:

45,383,085 5.71    

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:  
Details, including nature of the rights concerned and relevant percentages:  

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant security   Purchase/sale   Number of securities   Price per unit
Ordinary Purchase 2,600 ¥4,087
Ordinary Purchase 2,500 ¥4,013.4
Ordinary Sale 500 ¥4,084
Ordinary Sale 100 ¥4,051
Ordinary Sale 700 ¥4,095
Ordinary Sale 500 ¥4,015
Ordinary Sale 700 ¥4,086
Ordinary Sale 1,000 ¥4,057
Ordinary Sale 2,000 ¥4,061
Ordinary Sale 600 ¥4,081
Ordinary Sale 300 ¥4,024
Ordinary Sale 1,800 ¥4,066
Ordinary Sale 100 ¥4,012
Ordinary Sale 2,300 ¥4,063
Ordinary Sale 900 ¥4,034
Ordinary Sale 1,800 ¥4,064
Ordinary Sale 600 ¥4,088
Ordinary Sale 600 ¥4,046
Ordinary Sale 2,000 ¥4,039
Ordinary Sale 1,900 ¥4,065
Ordinary Sale 1,400 ¥4,082
Ordinary Sale 1,200 ¥4,085
Ordinary Sale 700 ¥4,041
Ordinary Sale 400 ¥4,056
Ordinary Sale 900 ¥4,059
Ordinary Sale 300 ¥4,017
Ordinary Sale 300 ¥4,052
Ordinary Sale 1,000 ¥4,054
Ordinary Sale 1,900 ¥4,060
Ordinary Sale 800 ¥4,043
Ordinary Sale 200 ¥4,096
Ordinary Sale 400 ¥4,091
Ordinary Sale 1,900 ¥4,074
Ordinary Sale 2,500 ¥4,042
Ordinary Sale 400 ¥4,026
Ordinary Sale 100 ¥4,068
Ordinary Sale 100 ¥4,016
Ordinary Sale 100 ¥4,047
Ordinary Sale 1,600 ¥4,078
Ordinary Sale 500 ¥4,031
Ordinary Sale 200 ¥4,028
Ordinary Sale 100 ¥4,033
Ordinary Sale 800 ¥4,025
Ordinary Sale 100 ¥4,094
Ordinary Sale 1,100 ¥4,083
Ordinary Sale 300 ¥4,070
Ordinary Sale 3,200 ¥4,062
Ordinary Sale 300 ¥4,055
Ordinary Sale 1,900 ¥4,013
Ordinary Sale 100 ¥4,009
Ordinary Sale 1,400 ¥4,038
Ordinary Sale 400 ¥4,021
Ordinary Sale 100 ¥4,099
Ordinary Sale 500 ¥4,089
Ordinary Sale 300 ¥4,018
Ordinary Sale 500 ¥4,045
Ordinary Sale 300 ¥4,014
Ordinary Sale 2,000 ¥4,079
Ordinary Sale 700 ¥4,092
Ordinary Sale 1,600 ¥4,075
Ordinary Sale 400 ¥4,058
Ordinary Sale 900 ¥4,001
Ordinary Sale 1,500 ¥4,073
Ordinary Sale 400 ¥4,080
Ordinary Sale 1,200 ¥4,072
Ordinary Sale 800 ¥4,069
Ordinary Sale 900 ¥4,071
Ordinary Sale 1,600 ¥4,077
Ordinary Sale 2,200 ¥4,076
Ordinary Sale 600 ¥4,087
Ordinary Sale 300 ¥4,053
Ordinary Sale 500 ¥4,090
Ordinary Sale 300 ¥4,008
Ordinary Sale 600 ¥4,022
Ordinary Sale 700 ¥4,037
Ordinary Sale 500 ¥4,004
Ordinary Sale 800 ¥4,035
Ordinary Sale 200 ¥4,093
Ordinary Sale 2,100 ¥4,040
Ordinary Sale 100 ¥4,097
Ordinary Sale 300 ¥4,029
Ordinary Sale 700 ¥4,044
Ordinary Sale 400 ¥4,036
Ordinary Sale 1,000 ¥4,067

(b) Cash-settled derivative transactions

Class of relevant security   Product description

e.g. CFD

  Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

  Number of reference securities   Price per unit

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security   Product description e.g. call option   Writing, purchasing, selling, varying etc.   Number of securities to which option relates   Exercise price per unit   Type

e.g. American, European etc.

  Expiry date   Option money paid/ received per unit

(ii) Exercise

Class of relevant security   Product description

e.g. call option

  Exercising/ exercised against   Number of securities   Exercise price per unit

(d) Other dealings (including subscribing for new securities)

Class of relevant security   Nature of dealing

e.g. subscription, conversion

  Details   Price per unit (if applicable)

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state “none”

None

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached? NO
Date of disclosure:   9/1/2019
Contact name: Taishi Fukuda
Telephone number: +81-3-5533-9508

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

Nippon Life Insurance Company

Recent news on Takeda Pharmaceutical Co

See all news